Investor News

INVESTOR NEWS

2020

27. November 2020 - Preliminary IFRS third quarter 2020 results

MPH Health Care AG: Preliminary IFRS third quarter 2020 results published. Equity (net asset value) amounts to € 194.39 million. This corresponds to € 45.40 per share.

Berlin, 27 November 2020: MPH Health Care AG (ISIN: DE000A0L1H32) announces preliminary IFRS results for the third quarter of 2020.

Accordingly, the equity of the investment company as of 30 September 2020 amounts to 194.39 million euros (30 September 2019: 239.57 million euros). The net asset value (NAV) per share as of 30 September 2020 is 45.40 euros (30 September 2019: 55.96 euros).

The preliminary IFRS net result for the first nine months of the 2020 financial year is EUR -77.25 million (30 September 2019: EUR -21.00 million). The reason for the net loss for the period is mainly due to the fair value measurement of the share prices of the investments on 30 September 2020 as of the reporting date compared to the share prices on 31 December 2019. The share prices of the MPH investment companies have fallen in the course of this year’s turbulence on the stock markets and have not yet been able to reach their level of the previous year.

“We are confident about the further development of our listed investments CR Capital Real Estate AG, M1 Kliniken AG despite this year’s share price decline. The two direct investments M1 and CR are developing positively in operational terms. At HAEMATO – now an indirect investment – important measures to expand the product portfolio and increase earnings are also being implemented”, says Patrick Brenske, member of the board of MPH.

read more

22. September 2020 - Capital reduction

Company announcement

Announcement of the ordinary capital reduction in accordance with §§222 et seq. AktG

The Annual General Meeting of our company on 22 July 2020 resolved, among other things, to reduce the share capital of the company from EUR 42,813,842.00 by EUR 2.00 to EUR 42,813,840.00, divided into 42,813,840 no-par value shares. The capital reduction will be carried out by withdrawing two no-par value shares with a proportionate amount of the Company’s share capital of EUR 1.00 per share. The total amount of the share capital attributable to the retired shares of EUR 2.00 will be allocated to the Company’s capital reserves in accordance with Article 237 (5) of the German Stock Corporation Act.

The sole purpose of the capital reduction is to create a smooth merger ratio for the further capital reduction.
The Company’s share capital of EUR 42,813,840.00, divided into -42,813,840 no-par value shares, is reduced by EUR 38,532,456.00 to EUR 4,281,384.00, divided into -4,281,384 no-par value bearer shares, in order to create a free capital reserve.

The further reduction is carried out in accordance with the provisions on ordinary capital reduction (§§ 222 et seq. AktG) in the ratio of 10:1. It is carried out in such a way that 10 no-par-value bearer shares are combined into one no-par-value bearer share with a notional share in the share capital of EUR 1.00.

The resolutions on the capital reduction and the corresponding amendment to the Articles of Association were entered in the commercial register of the Company on 13 August 2020 and thus became effective; since then, the share capital of the Company has been effectively reduced.

With record day 23 September 2020 in the evening and value date 24 September 2020, the shares held in collective safe custody by the custodian institutions and Clearstream Banking AG, Frankfurt am Main, will be pooled at a ratio of 10:1. For every 10 old shares ( ISIN DE000A0L1H32), shareholders will receive one new converted share ( ISIN DE000A289V03) with a pro-rata amount of the share capital of EUR 1.00. The converted shares are entitled to participate in profits from 1 January 2020.

In accordance with the Articles of Association, shareholders are not entitled to individual certification of their shares. The reduced share capital was securitised in a global certificate deposited with Clearstream Bank AG, Frankfurt am Main. The previous percentage share of a shareholder in the share capital of MPH Health Care AG remains unchanged.

If a shareholder holds a number of no-par value shares that cannot be divided by 10, fractional shares ( ISIN DE000A289VT5) are booked to his account.

A rounding off to full rights (so-called peak regulation) requires a corresponding buy or sell order. In order to carry out the necessary peak regulation, the shareholders of MPH Health Care AG are requested to notify their respective custodian bank as soon as possible, but no later than October 8, 2020

to issue an appropriate order because of the treatment of fractional shares, in particular the sale of fractional shares or the purchase of additional fractional shares for the purpose of rounding them into one share. The custodian banks will endeavour to compensate for fractional shareholdings in accordance with the instructions of their customers.

Remaining share fractions will be written off by Clearstream Banking AG after the end of 08 October 2020 and transferred to the central settlement agent, Bankhaus Gebr. Martin AG, for further realisation.

MPH Health Care AG will not refund any fees.

The price determination for the converted shares resulting from the capital reduction with the new ISIN DE000A289V03 in the Regulated Unofficial Market of the Frankfurt Stock Exchange will commence on 22 September 2020. Existing stock exchange orders expire at the end of 21 September 2020.

Berlin, September 2020

read more

2. September 2020 - MPH Health Care AG: 1st half of 2020

Portfolio companies partly affected by corona restrictions. Net Asset Value (NAV) is at 5.58 Euro

Berlin, 02 September 2020. MPH Health Care AG (ISIN: DE000A0L1H32) today reports on the development of the company and the investment portfolio in the first half of 2020. The company’s Net Asset Value (NAV) at the end of the first half of 2020 was 5.58 euros per share (previous year 5.86 euros per share). Due to the current uncertainties in connection with the corona pandemic, the listed investments HAEMATO AG and M1 Kliniken AG each decided at their annual general meetings in July 2020 not to pay dividends in order to strengthen liquidity. The shareholders of MPH AG also decided on 22 July 2020 at the Annual General Meeting not to pay a dividend for the past financial year 2019 in order to maintain sufficient financial reserves for further growth.

MPH’s listed and major associated companies developed as follows in the first half of 2020:

HAEMATO AG was able to ensure the regular course of business as far as possible despite the corona restrictions with numerous organisational measures and to guarantee a constant supply of goods to customers. With a turnover of 115.8 million Euros in the first half of 2020 the company exceeded the previous year’s value by a good 23 %. EBITDA for the first six months amounts to TEUR 2,066, which is also around 23 % above the comparable figure for the previous year of TEUR 1,675. The equity ratio as of 30 June 2020 increased from 56.2 % (previous year) to 61.3 %.

In the first quarter of 2020, M1 Kliniken AG was able to continue its strong growth course of the 2019 financial year. Three new practices (London, Liverpool and Graz) have already been opened. For the second half of 2020, further practice openings are firmly on the agenda.
In the course of the corona pandemic, however, the practices and clinics had to close from 23 March 2020 and could only be reopened step by step in the course of May. Although the M1 is experiencing an ongoing increase in demand for medical and aesthetic services, the two-month closure resulted in a loss of revenue. IFRS consolidated sales in the first half of 2020 amounted to EUR 29.1 million compared to EUR 32.9 million in the first half of 2019. Earnings before taxes (EBT) for the reporting period fell to TEUR 2,523 (after TEUR 5,183 as of 30 June 2019).

For CR Capital Real Estate AG, the fiscal year 2019 developed very positively. In order to set the course for future growth and the expansion of the business model towards a real estate investment company, accounting was changed to IFRS 10 at the end of last year. Due to the valuation of the investments of CR Capital Real Estate AG at fair value, the net income for the year increased to more than EUR 90 million (previous year: EUR 7.8 million). Equity rose to approx. EUR 200 million (previous year: EUR 35.4 million).
At the end of July 2020, CR Capital Real Estate AG announced its intention to establish a real estate investment company in the legal form of a Real Estate Investment Trust (REIT AG) together with financial investors. Investments will mainly be made in newly built residential properties in Berlin and in the Berlin suburbs. With the future REIT AG, CR Capital Real Estate AG will offer private investors lucrative and tax-advantageous investment opportunities in real estate even for smaller amounts.

The half-year report 2020 of MPH Health Care AG is available for download at: www.mph-ag.de/investor-relations.

read more

10. June 2020 - Transfer of all shares owned in HAEMATO AG to M1 Kliniken AG

MPH Health Care AG: Transfer of all shares owned in HAEMATO AG to M1 Kliniken AG within the framework of a capital increase through contributions in kind

Berlin, 10.06.2020 – The management boards of MPH Health Care AG and M1 Kliniken AG today signed an agreement for the acquisition of all 11,011,977 HAEMATO AG shares owned by MPH Health Care AG by M1 Kliniken AG. MPH Health Care AG is transferring the shares of HAEMATO AG to M1 Kliniken AG in a capital increase through contribution in kind. For this purpose, the Management Board of M1 Kliniken AG today resolved, with the approval of the Supervisory Board, to increase the company’s share capital by EUR 2,143,403.00 to EUR 19,643,403.00 by issuing 2,143,403 new shares of M1 Kliniken AG through a capital increase against contribution in kind, excluding the subscription rights of shareholders, using the existing authorised capital. The new shares will be subscribed exclusively by MPH Health Care AG. The contribution in kind will be made with effect from 1.07.2020.

With this transaction, MPH Health Care AG supports the core competencies of its investments active in the medical sector. With its ISO13485 certification as well as a manufacturing licence in accordance with § 13 AMG and a wholesale licence in accordance with § 52 AMG, the HAEMATO Group has the core prerequisites for the development of branded products within the self-payer segment. M1 Kliniken AG is one of the leading international providers of beauty medical treatments with several hundred thousand treatments per year and a dedicated growth strategy for the coming years.

read more

29. May 2020 - First Quarter 2020: Peliminary IFRS results

First quarter 2020: Preliminary IFRS result, equity
(Net Asset Value) 184.17 million euros, or 4.30 euros per share.

Berlin, 29 May 2020: MPH Health Care AG (“MPH”) announces its preliminary IFRS results for the first quarter of 2020. Accordingly, the preliminary IFRS equity as of 31 March 2020 amounts to EUR 184.17 million (as of 31 December 2019: EUR 271.64 million).

The reason for the decrease in equity is the fair value measurement of the share prices of the investments at the reporting date of 31 March 2020 compared to the share prices at 31 December 2019, which is mainly influenced by the general negative development on the global stock markets in the wake of the corona pandemic in the first quarter of 2020..

The Net Asset Value (NAV) decreased year-on-year from EUR 6.15 to EUR 4.30 per share, but is still well above the Xetra closing price of EUR 2.74 per share on March 31, 2020.

“The further development of our listed shareholdings M1 Kliniken AG, HAEMATO AG and CR Capital Real Estate AG in 2020 is, inter alia, marked by the general economic development in the context of the corona crisis as well as possible catch-up effects from the second half of 2020, provided that there is further easing and a “normalization” of business life. We are already seeing the first signs of this.

Our investment M1 Kliniken AG has now reopened almost all its facilities on the basis of a strict security and hygiene concept. Despite extended treatment intervals, a sales level comparable to the “pre-corona business volume” was already achieved in the first week. In addition, the clinics are almost completely booked out for a period of several weeks. M1 therefore assumes that the closure period and other effects of the corona pandemic will not have a long-term and sustainable impact on the Group’s business model.

Our investment HAEMATO AG continues to systematically benefit from the growth of the health care and pharmaceutical market in Germany and was able to increase sales in the first quarter of 2020 by about 25 % compared to the previous year. As part of the renewal of the product portfolio, HAEMATO was able to place 38 medical drugs on the market during this period for newly granted approvals (i.e. products)..

Our third listed investment, CR Capital Real Estate AG, has so far not experienced any restrictions due to the corona pandemic and continues to record a high demand for affordable housing”, says Patrick Brenske, member of the Managing Board of MPH.

The Annual Report 2019 of MPH Health Care AG was published on the website on May 27, 2020. The net asset value could be increased in the financial year 2019 from 6.29 euros to 6.34 euros per share. The IFRS consolidated net profit in the financial year 2019 amounted to EUR 11.08 million (previous year EUR 37.03 million).

read more

27. May 2020 - Annual Report 2019

MPH Health Care AG publishes Annual Report 2019 – shortened deadlines for Annual General Meeting on 22 July 2020

  • Consolidated net income (IFRS) 11.08 million euros
    (previous year 37.02 million euros)
  • Increase in equity (IFRS) to 271.64 million euros
    (previous year 269.13 million euros). Increase of Net Asset Value to Euro 6.34 per share (previous year Euro 6.29 per share)
  • Annual General Meeting still scheduled for 22.07.2020 – shortened deadlines

Berlin, 27 May 2020: MPH Health Care AG (“MPH”) today published its Annual Report for the 2019 financial year. According to this, the consolidated net income for the year according to IFRS accounting amounted to EUR 11.08 million (previous year EUR 37.02 million). Shareholders’ equity increased from EUR 269.13 million on 31 December 2018 to EUR 271.64 million on 31 December 2019. The NAV (Net Asset Value) increased accordingly from EUR 6.29 per share as of 31 December 2018 to EUR 6.34 per share as of 31 December 2019.

The consolidated financial statements for 2019 were adopted by the Supervisory Board in its meeting on 12 May 2020.

The Annual Report 2019 of MPH Health Care AG is available for download at www.mph-ag.de/finanzberichte/.

According to current planning, the Annual General Meeting of MPH Health Care AG is still scheduled to take place on 22 July 2020. For this purpose, the company is monitoring the further development of the corona pandemic in order to decide on this basis whether to hold either a face-to-face meeting or a virtual general meeting. For this purpose, the Company will work with shortened loading and notification periods. The invitation to the Annual General Meeting will probably be published in the Federal Gazette towards the end of week 26.

Download corporate news as PDF

read more

12. May 2020 - Supervisory Board approves 2019 financial statements

MPH Health Care AG: Supervisory Board approves 2019 financial statements. Proposal of the Executive Board to carry forward the entire 2019 balance sheet profit confirmed.

Berlin, 12.05.2020 – In its balance sheet meeting today, the Supervisory Board of MPH Health Care AG (ISIN: DE000A0L1H32) approved the annual financial statements and the consolidated financial statements of the company presented by the Management Board for the 2019 financial year in accordance with §§ 171, 172 of the German Stock Corporation Act (AktG). The annual financial statements are thus adopted in accordance with § 172 AktG.

The Supervisory Board confirmed with the Management Board’s proposal to carry forward the net profit for the 2019 financial year in full to new account. This is intended to secure the Company’s liquidity.

The Annual Report 2019 of MPH Health Care AG is expected to be published on May 29, 2020.

read more

16. April 2020 - Preliminary IFRS result 2019

MPH Health Care AG: Preliminary IFRS result 2019

  •  Net income for the year 11.08 million Euro, earnings per share 0.26 Euro (previous year 37.02 million Euro, earnings per share 0.86 Euro).
  • The net asset value was Euro 6.34 per share (previous year Euro 6.29).

Berlin, 16 April 2020: MPH Health Care AG, Berlin (ISIN: DE000A0L1H32), announces its preliminary IFRS consolidated results for the 2019 financial year. In the 2019 financial year, the preliminary IFRS net profit for the year was EUR 11.08 million (EUR 0.26 earnings per share). The (preliminary) shareholders’ equity rose from Euro 269.13 million to Euro 271.64 million.

M1 Kliniken AG and CR Capital Real Estate AG, both listed on the Frankfurt Stock Exchange, continued their successful operations in fiscal 2019. At HAEMATO AG, which is also listed on the Frankfurt Stock Exchange, important measures to increase earnings and digitalisation were implemented in the past fiscal year.

M1 Kliniken AG performed fiscal year (previous year 190,000), thus further extending its market leadership. A key element to this is the further increase in the number of M1 specialist centres, which rose by 50% from 24 specialist centres (as of 31 December 2018) to 36 specialist centres as of 31 December 2019. Expansion abroad was also continued: Following the opening of the first M1 specialist centre in Vienna at the end of 2018, a total of 8 locations in Austria, Australia, the Netherlands and Switzerland were in operation at the end of 2019. The expansion of the product range to include aesthetic laser treatments (M1 laser) was also continued in 2019. Laser treatments are now offered at over 20 locations. The expansion will continue in the coming years with the target of operating a total of 100 specialist centres by the end of 2023.

M1 Kliniken AG was able to increase (preliminary) IFRS revenues by around 18 % to EUR 77.2 million and (preliminary) net income after taxes by around 47% to EUR 9.7 million. The (preliminary) equity capital has increased by around 7% to 68.2 million euros as of 31.12.2019. The M1 share price fell slightly from Euro 15,00 on December 31, 2018 to Euro 14.30 on December 31, 2019.

In the fiscal year 2019, CR Capital Real Estate AG was able to increase its (preliminary) IFRS net income to more than EUR 90 million (previous year: EUR 7.8 million), while the (preliminary) equity rose to approx. EUR 200 million (previous year: EUR 35.4 million). In order to set the course for future growth and the expansion of the business model towards a real estate investment house, accounting was changed to IFRS 10.

Following the share split, the share price of CR Capital Real Estate AG rose sharply from (converted) Euro 16.50 on December 31, 2018 to Euro 32.60 on December 31, 2019.

In the fiscal year 2019, HAEMATO AG generated (preliminary) IFRS consolidated sales revenues of Euro 197.8 million (previous year Euro 274.1 million), a balanced operating result (EBIT, previous year Euro 6.6 million) and a net loss for the year of Euro 1.2 million (previous year net income of Euro 6.3 million). With an equity ratio of 56.2 % (previous year 65.0 %), the company continues to be well positioned.

The share price of HAEMATO AG has decreased from 4.65 Euro on December 31, 2018 to 2.94 Euro on December 31, 2019. The measures and investments initiated in the business year 2019 to increase earnings and digitalization will probably take effect from 2020. The Management Board of HAEMATO AG continues to work on the optimization of its business processes and the approval of new products and product groups to broaden the portfolio.

“The development in 2020 currently depends largely on the further development of the Covid-19 pandemic. Therefore, no serious statements can be made at this time about the duration and consequences of this extraordinary, global crisis, which has hit almost every industry unexpected. However, we are confident that some of our investments will be able to take advantage of opportunities in this special situation, e.g. HAEMATO AG with the distribution of special drugs as well as M1 Kliniken AG, which can contribute to the diagnosis of the corona pandemic with its Europe-wide network of clinics and medical practices. MPH would also systematically benefit from this.

With regard to the distribution of a dividend for the financial year 2019, the Management Board and Supervisory Board will submit a suitable proposal in time for the Annual General Meeting,” said Patrick Brenske, MPH’s CEO. He added: “The current developments of our portfolio companies in the wake of the global turbulence on the stock markets as a result of the Covid-19 pandemic could possibly lead to some of our investments not paying a dividend for the past financial year in order to have sufficient financial reserves at their disposal. As soon as a return to “normal” business operations is achieved, MPH will – as in the past – allow its shareholders to participate in the company’s success accordingly”.

It is also planned to expand the portfolio this year and next year to include telemedicine and mail-order pharmacies. For this purpose, MPH Ventures GmbH has founded a mail-order pharmacy in the Netherlands within the “Ventures” division of MPH through one of its subsidiaries in the first quarter of 2020.

 

read more

2019

29. October 2019 - Preliminary IFRS result for third quarter of 2019

Preliminary IFRS result for third quarter of 2019: NAV per share at EUR 5.60 still well above current stock level

Berlin, October 29, 2019: MPH Health Care AG (ISIN: DE000A0L1H32) announces preliminary IFRS results for the third quarter of 2019. The equity of the investment company amounted to EUR 239.57 million as of September 30, 2019 (previous year: EUR 281.00 million). The net asset value (NAV) per share was Euro 5.60 (previous year: Euro 6.56) and thus still well above the current price level (Xetra closing price 28 October 2019: Euro 3,72).

The decline in the share price of HAEMATO AG from EUR 4.65 per share (31.12.2018) to EUR 3.01 per share on 30.09.2019 in particular led to a decline in the NAV. HAEMATO AG has taken extensive measures to increase earnings (e.g. streamlining the product portfolio) and is currently in the process of establishing new personnel and digital structures in the product management, procurement and sales divisions.

“We are confident about the further development of our listed investments HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG despite the short-term decline in the share price. M1 and CR in particular are developing very positively in operational terms and HAEMATO is currently implementing important measures to increase earnings,” says Patrick Brenske, member of the Management Board of MPH.

read more

29. August 2019 - Interim Report 2019

1st half-year 2019 of MPH Health Care AG: Investment companies develop according to plan and net asset value (NAV) of EUR 5.86 significantly above current share price

Berlin, 29. August 2019. The net asset value (NAV) of MPH Health Care AG (ISIN: DE000A0L1H32) was EUR 5.86 per share at the end of the first half of 2019, well above the current share price (Xetra closing price 28 August: EUR 3.89). Due to the continuing good results of the investments, MPH again distributed a dividend of 20 cents per share in July 2019. This corresponds to a dividend yield of 5,1%.

MPH’s listed and significant equity investments developed according to plan in the first half of 2019:

CR Capital Real Estate AG has increased its dividend for the 2018 financial year by 50% to EUR 1.50 per share and also resolved to issue new no-par value shares (bonus shares) at a ratio of 1:1. In the first six months of the current year, the company continued its positive business development. Sales amounted to EUR 6.32 million (H1/2018: EUR 12.83 million). The real estate company significantly increased its net income for the first half of the year from EUR 2.10 million to EUR 3.47 million. Currently, two projects are in the construction phase and others are in concrete development. For 2019 as a whole, the company expects earnings growth of around 30 percent. In addition to its positive operating performance, CR Capital Real Estate has expanded its business model in recent months. In the future, social housing will be another focus area. Thanks to its proven price-conscious design, CR is well placed to enter the social housing segment and create added value for both tenants and shareholders.

At its Annual General Meeting, M1 Kliniken AG approved the distribution of a dividend for 2018 of EUR 0.30 per share. Demand for the medical aesthetic services of the M1 Group continued to develop positively in the first half of 2019. Group sales rose from EUR 28.9 million to EUR 32.9 million. Germany’s market leader in the field of beauty medicine is profiting more and more from the investments made in recent years. The growth driver in the first half of the year was the strong-margin core segment “Beauty”, whose sales increased by more than 40 percent to EUR 20.3 million. Earnings before taxes (EBT) rose in the reporting period by 21 percent to EUR 5.2 million. In addition to the positive operating development, the M1 Group also set the course for further growth in Germany and abroad in the reporting period. Four further specialist centres were opened until end of July. In addition, treatment capacities were expanded at several German locations. The M1 Group has already established cosmetic laser treatments in ten beauty centres and is successfully exploiting cross-selling potential. By the end of the year, the services of “M1 Laser” are to be offered in almost all German locations. Based on this positive business development, M1 Kliniken has confirmed its operating targets for 2019: Double-digit increase in Group sales and earnings. In the second half of 2019, numerous new locations in Germany and abroad will be added and will contribute to the Group’s operational growth in the future.

HAEMATO AG has approved a dividend of EUR 0.10 per share for 2018. The product portfolio is currently being realigned and internal processes optimized and digitized. The pharmaceutical company, which focuses on the growth markets of high-priced special pharmaceuticals, is currently establishing new personnel and digital structures in product management, procurement and sales in order to exploit the existing market potential more extensively in the future. As expected, the company’s operating performance in the first half of the year was significantly below the previous year’s level. HAEMATO achieved sales of EUR 94.0 million and earnings before interest and taxes (EBIT) of EUR 0.7 million. After HAEMATO adjusted its product portfolio for low-margin products last year, capacities are now available for the introduction of new products. This includes the trading of narcotics (including medical cannabis) and the development of medical products. This means broadening the product range in segments with above-average growth.

The Half Year Report 2019 of MPH Health Care AG for download: www.mph-ag.de/investor-relations

read more

18. July 2019 - HV 2019

MPH Health Care AG successfully holds Annual General Meeting – Dividend distribution of EUR 0.20 per share resolved

Berlin, July 18th, 2019: MPH Health Care AG (“MPH”) successfully held the Annual General Meeting 2019 yesterday. The resolution on all items on the agenda of this year’s Annual General Meeting was passed with a majority of more than 99%.

A total of 56% of the share capital was represented at the Annual General Meeting. The items on the agenda included the resolution on the appropriation of the 2018 balance sheet profit, the ratification of the actions of the members of the Management Board and Supervisory Board and the election of the auditor for the 2019 financial year.

The shareholders followed the proposal of the Management Board and Supervisory Board to distribute a dividend of EUR 0.20 per share for the 2018 financial year with a large majority. All other resolutions were also approved by a large majority. The detailed voting results were published at: https:// www.mph-ag.de/investor-relations/.

The dividend is due on Monday, 22 July 2019.

About MPH Health Care AG:About MPH Health Care AG:MPH AG is an investment company with a strategic focus on the acquisition, development and sale of companies and company shares, particularly in growth segments of the healthcare market. This includes both insurance-financed and privately financed segments. However, MPH also exploits the potential of high-growth and high-yield sectors outside the healthcare market.

MPH Health Care AG shares are listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange.

Key figures for the MPH Health Care AG shares:

Subscribed capital: EUR 42,813,842
Listed class of shares: Bearer ordinary shares
ISIN: DE000A0L1H32
Security identification number: A0L1H3
stock exchange code: 93M

read more

23. May 2019 - Q1 Results 2019

Corporate News of MPH Health Care AG: Q1 Results

First Quarter 2019: Preliminary IFRS-result, equity (Net Asset Value) of 263.49 million EUR and therefore 6.15 EUR per share.

Berlin, 23rd May, 2019: MPH Health Care AG (ISIN: DE000A0L1H32) announces preliminary IFRS results for the first quarter of 2019. Accordingly, the preliminary IFRS period loss amounted to -5.64 million EUR (previous year: period profit of 26.75 million EUR). The reason for the net loss for the period lies in the fair value measurement of the share prices of the investments on 31 March 2019 compared to the share prices on 31 December 2018.

Equity amounted to 263.49 million EUR as of 31 March 2019 (previous year: 267.42 million EUR). Net asset value (NAV) fell slightly year-over-year from 6.25 EUR (31 March 18) to 6.15 EUR (31 March 19) per share.

“We are confident about the further development of our listed investments HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG in 2019, despite the brief decline in the share price. The healthcare market in Germany has been growing faster than the economy as a whole for many years now, and we are systematically benefiting from this with our investments, e.g. with HAEMATO for pharmaceuticals in the insurance-financed market and with M1 Kliniken in the private payer market,” says Patrick Brenske, CEO of MPH.

Due to the sustained positive results of recent years, the Executive Board will propose an unchanged dividend of 20 cents per share at the Annual General Meeting on 17 July 2019.

The Annual Report 2018 of MPH Health Care AG was published on the website on May 22, 2019 and is available for download at https://www.mph-ag.de/en/en/reports/. Net asset value increased by 12% from 5.62 EUR (31 Dec. 17) to 6.29 EUR (31 Dec. 18) per share in the fiscal year 2018.

read more

11. April 2019 - Preliminary IFRS result 2018

MPH Health Care AG: Preliminary IFRS result 2018

2018: Net income 37.03 million euro, earnings per share 0.87 euro (previous year 31.86 million euro, earnings per share 0.74 euro). The net asset value was euro 6.29 per share (previous year euro 5.62).

Berlin, April 11, 2019: Preliminary IFRS result: MPH Health Care AG, Berlin (ISIN: DE000A0L1H32), announces preliminary IFRS consolidated result for fiscal year 2018. In the 2018 financial year, the preliminary IFRS net income amounted to 37.03 million euro (0.87 euro earnings per share).

HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG, which are listed on the Frankfurt Stock Exchange, continued to operate successfully in the 2018 financial year.

HAEMATO AG was able to achieve consolidated sales of 274.1 million euro, an EBITDA of 10.0 million euro and a net profit of 6.3 million euro (according to IFRS 15). The improvement in operating gross profit was just under 1 %. Financial liabilities were reduced significantly by a total of euro 10.9 million, based on the cancellation of the profit participation certificates. The Management Board has announced that the Supervisory Board will propose an unchanged dividend of 30 cents per share for the 2018 financial year.

M1 Kliniken AG was able to increase the number of treatments performed in the past financial year to almost 190,000, further extending its market leadership. A key element here is the further increase in the number of M1 specialist centres from 17 (as 31.12.2017) to 24 (as 31.12.2018). The international expansion was initiated with the first M1 specialist centre in Vienna. In 2018, the product range was expanded to include aesthetic dental and laser treatments with M1 Dental and M1 Laser. The continuation of the expansion to a total of 50 specialist centres is planned for 2020.

The M1 share price rose from euro 13.20 on January 2, 2018 to euro 15.00 on December 31, 2018. In September 2018, the share capital was increased by € 1,000,000.00 to euro 17,500,000.00 by means of a capital increase through the issue of a total of 1,000,000 bearer shares. The dividend paid in June 2018 amounted to 30 cents per share.

CR Capital Real Estate AG was again able to significantly increase its net profit for the 2018 financial year by 33% to euro 7.7 million, whitch is euro 1.9 million above the previous year’s result of euro 5.8 million. Sales increased by +123% to euro 23.2 million, earnings per share by +30% to euro 4.10 (previous year euro 3.14). The share price of CR Capital Real Estate AG increased from euro 20.80 on January 2, 2018 to euro 32.60 on December 31, 2018. Due to the extremely positive result, the Management Board proposes to increase the dividend for the 2018 financial year and to issue bonus shares, which would be fully entitled to dividends from the 2019 financial year onwards.

“We are confident about the further development in 2019. Since 2005, the healthcare industry has expanded its gross value added more strongly than the economy as a whole every year. MPH benefits systematically from the growth of HAEMATO AG with drugs in the insurance-financed market and M1 Kliniken AG in the private payer market, the so-called second health market. This is also reflected in the comparison of the share price performance with the SDAX.

In recent years, a dividend of 12 cents has been distributed, and for the 2017 financial year a dividend of 20 cents per share has been distributed. Due to the continuing positive results of recent years, we will again propose a dividend of 20 cents per share for 2018 at the Annual General Meeting,” said Patrick Brenske, CEO of MPH.

read more

2018

3. December 2018 - 2018 Developing

MPH Health Care AG: Investments developing positive

  •  CR Capital Real Estate raises sales and profit forecast
  • Haemato increases earnings by approx. 50% in the first 9 months
  • M1 Kliniken opens further locations

Berlin, 03 December 2018: The affiliated companies of MPH Health Care AG (ISIN: DE000A0L1H32) have confirmed their growth course with positive news.

CR Capital Real Estate AG has significantly increased its sales and profit forecast for the current year 2018. The real estate company focuses on the creation of affordable living space in the metropolises of Berlin and Leipzig and their environs. Group sales in 2018 are expected to increase from EUR 10.4 million in the previous year to over EUR 20 million. The annual surplus is to rise from 5.8 million euros to over 7 million euros. The project in Schkeuditz with 96 terraced houses is decisive for the positive development. In addition, plots close to Berlin were acquired. Here, too, semi-detached and terraced houses are expected to be built.

HAEMATO AG reported on the development in the first nine months of 2018. The provider of special pharmaceuticals increased its profit by 50.5 percent from EUR 3.9 million to EUR 5.87 million compared to the same period of the previous year. Sales increased slightly from EUR 211.3 million to EUR 212.8 million. HAEMATO specializes in drugs for the treatment of chronic diseases and sees further growth potential. In addition, the operating margin is to be increased sustainably. Therefor, the Executive Board is working on optimizing business processes through digitization.

M1 Kliniken AG, the number 1 in the field of beauty medicine in Germany, continues its expansion course in 2018. 4 new specialist centres have been opened so far this year. Two more are to follow by the end of the year. The M1 Group will thus operate a total of 24 specialist centres for aesthetic treatments by the end of 2018. The increase of more than 30% compared to the previous year is in line with corporate planning. M1 Kliniken AG is thus creating an important condition for a further significant increase in sales in the coming year.

read more

30. October 2018 - Q3 Results 2018

Investment company MPH Health Care AG increases net asset value by 27.6 % to EUR 6.56 per share as of 30.09.2018

  • Net income for the period of 48.90 million euros
  • Equity ratio increases to 94.2 %

Berlin, 30. Oktober 2018: MPH Health Care AG (ISIN: DE000A0L1H32) continued to benefit from the successful development of its portfolio companies in the first nine months of 2018. The net asset value (NAV) per share rose year-on-year by 27.6 % from EUR 5.14 to EUR 6.56 as of September 30, 2018. This means that the NAV is still well above the current share price (Xetra closing price on October 29, 2018: EUR 4.17).

In the first nine months of 2018, MPH generated a preliminary IFRS period surplus of EUR 48.90 million (previous year: EUR 11.22 million). This pleasing result was achieved through a corresponding increase in the value of financial investments. Compared with the end of 2017, equity rose from EUR 240.67 million to EUR 281.00 million.

“The health care and construction industries in Germany have been growing faster than the economy as a whole for years, and with our investments we benefit systematically, e.g. through the growth of HAEMATO AG with pharmaceuticals in the insurance-financed market, M1 Kliniken AG in the private payer market and CR Capital Real Estate AG in the affordable new residential constructions for owner-occupiers. We are therefore confident that this positive development will continue,” says Patrick Brenske, CEO of MPH.

read more

31. August 2018 - Interim Report 2018

Investment company MPH Health Care AG with successful first half-year of 2018: Net asset value rises by 43 % to EUR 6.93 per share

  • Net earnings EUR 55.9 million (previous year: EUR -2.2 million)
  • Investments: HAEMATO has more than doubled its EBIT; M1 Kliniken grows by 30 %; CR Capital benefits from great interest in the “Halle Gardens” construction project in Schkeuditz/Leipzig
  • Dividend payment of 20 cents per share (previous year: 12 cents) made in July

Berlin, 31 August 2018: MPH Health Care AG (ISIN: DE000A0L1H32) benefited from the successful development of its portfolio companies in the first half-year of 2018. The net asset value (NAV) per share rose year-on-year by 43.4 % from EUR 4.83 to EUR 6.93. With this, the NAV continues to exceed the current share price considerably (Xetra closing on August 30: EUR 4.54).

IFRS equity capital amounted to EUR 296.6 million at the reporting date of 30 June 2018 (H1 2017: EUR 206.6 million). MPH increased its net earnings (IFRS) in the first half-year of 2018 to EUR 55.9 million (H1 2017: EUR -2.2 million).

“Our listed investments in HAEMATO, M1 Kliniken and CR Capital Real Estate have continued their successful development in the first half-year of 2018,” says Patrick Brenske, CEO of MPH. “With our focus on growth companies of the German health care market, we systematically benefit from the industry’s above-average development compared to the overall economy. We were therefore able to pay a significantly higher dividend of 20 cents per share in July 2018.”

The three major portfolio companies of MPH Health Care AG recorded a positive development in the first half-year of 2018.

HAEMATO AG, a pharmaceutical company focusing on the growth markets of high-priced specialty pharmaceuticals, more than doubled its earnings before interest and taxes (EBIT) – with slightly increasing sales – to EUR 6.5 million compared to the previous year in the first half-year of 2018.

M1 Kliniken AG, a leading private provider of health services in the field of aesthetic medicine in Germany, continued its profitable growth course and increased Group sales by 30% to EUR 28.9 million. For the second half-year of 2018, not only additional M1 Med Beauty locations, but also further specialist centres for aesthetic dental treatments under the new brand “M1 Dental” are planned. In addition, M1 is targeting its internationalisation. The first international location is to be opened in Vienna in the second half of 2018.

CR Capital Real Estate AG, which focuses on project developments in the residential and health care real estate sectors, has successfully continued its current construction project “Halle Gardens” in Schkeuditz/Leipzig. The first residential units were handed over to the new owners in April. The complete handover of the first construction phase with 96 residential units is to take place until autumn 2018. Due to the high demand, CR has already acquired further adjacent areas and is planning further new buildings there. In addition, CR has secured plots in the Berlin surroundings, in attractive quality locations with good infrastructure.

 The Half Year Report 2018 of MPH Health Care will be available for download from www.mph-ag.de/investor-relations later today.

 

read more

13. July 2018 - hv_2018

Significant dividend increase from 0.12 EUR to 0.20 EUR per share approved

  • Dividend yield at 4 %
  • Annual general meeting approves all agenda items

Berlin, May 11, 2018: MPH Health Care AG (ISIN: DE000A0L1H32) will continue to benefit from the successful development of its associated companies in the current year. At MPH, this is reflected in the increase in the value of financial investments. In the first quarter of 2018, the associated company generated preliminary net income (IFRS) of EUR 26.75 million (previous year: EUR -2.39 million). Equity rose to EUR 267.42 million (previous year: EUR 211.56 million). Net asset value (NAV) rose year-on-year from EUR 4.94 to EUR 6.25 per share, well above the current share price.

“Our listed investments HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG have made a successful start to 2018,” says Patrick Brenske, CEO of MPH. “The healthcare market in Germany has been growing faster than the economy as a whole for years and we are systematically benefiting from this through our investments. With HAEMATO for drugs in the insurance-financed market and with M1 clinics in the private payer market. We are therefore confident that this positive development will continue.”

Due to the sustained positive results of recent years, the Executive Board will propose to the annual general meeting on July 11, 2018 a dividend increase from 12 cents per share to 20 cents per share for the financial year 2017.

The Annual Report 2017 of MPH Health Care AG is available for download at www.mph-ag.de//en/investor-relations

read more

11. May 2018 - Q1 Results 2018

Net asset value rises in Q1/2018 to EUR 6.25 per share and dividend for 2017 to be significantly increased

  • All investments develop positively
  • Dividend increase for 2017 from 12 cents to 20 cents per share

Berlin, May 11, 2018: MPH Health Care AG (ISIN: DE000A0L1H32) will continue to benefit from the successful development of its associated companies in the current year. At MPH, this is reflected in the increase in the value of financial investments. In the first quarter of 2018, the associated company generated preliminary net income (IFRS) of EUR 26.75 million (previous year: EUR -2.39 million). Equity rose to EUR 267.42 million (previous year: EUR 211.56 million). Net asset value (NAV) rose year-on-year from EUR 4.94 to EUR 6.25 per share, well above the current share price.

“Our listed investments HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG have made a successful start to 2018,” says Patrick Brenske, CEO of MPH. “The healthcare market in Germany has been growing faster than the economy as a whole for years and we are systematically benefiting from this through our investments. With HAEMATO for drugs in the insurance-financed market and with M1 clinics in the private payer market. We are therefore confident that this positive development will continue.”

Due to the sustained positive results of recent years, the Executive Board will propose to the Annual General Meeting on July 11, 2018 a dividend increase from 12 cents per share to 20 cents per share for the financial year 2017.

The Annual Report 2017 of MPH Health Care AG is available for download at www.mph-ag.de/investor-relations

read more

29. March 2018 - Ad hoc – Preliminary IFRS result 2017

Ad hoc of MPH Health Care AG: Preliminary IFRS result 2017

2017: Preliminary IFRS result, net income 31.86 million euros, earnings per share 0.74 euros (previous year: 80.07 million euros, earnings per share 1.87 euros). Equity EUR 240.67 million (previous year: EUR 213.95 million). Net Asset Value per share of EUR 5.62.

MPH Health Care AG, Berlin (ISIN: DE000A0L1H32), announces its preliminary consolidated IFRS results for the financial year 2017. The preliminary IFRS net income amounted to EUR 31.86 million (EUR 0.74 earnings per share).

HAEMATO AG, which is listed on the Frankfurt Stock Exchange, M1 Kliniken AG and CR Capital Real Estate AG continued to operate successfully in the financial year 2017.

HAEMATO AG was able to increase the consolidated IFRS sales by 5 % to 289.9 million Euro and thereby achieve an EBIT of 9.4 million Euro and a net income of 7.0 million Euro. As in previous years, the dividend paid in June 2017 was 30 cents per share.

M1 Kliniken AG was able to significantly increase its consolidated sales by 31 % to Euro 47.2 million and EBT by 36 % to Euro 7.4 million. In particular, this was due to the opening of six new medical centers in 2017, bringing the total number of M1 centers serving customers nationwide as of December 31, 2017 to 17. The M1 share price rose from EUR 10.80 to EUR 13.18 during the year. The dividend paid in June 2017 was 30 cents per share.

CR Capital Real Estate AG more than doubled its net income to EUR 4.7 million in fiscal year 2017 (previous year: EUR 2.2 million). The consolidated IFRS sales fell to ca. EUR 10.0 million (previous year: EUR 17.5 million). As a result of an ordinary capital reduction pursuant to §§ 222 ff. the stock price of CR Capital Real Estate AG increased from (converted) EUR 19.00 to EUR 20.31 during the year. Due to the extremely positive result, a dividend of EUR 1.00 per share (previous year no dividend) is planned for fiscal 2017.

“We are confident about the further development in 2018. Since 2005, every year the healthcare industry has expanded its gross value added more strongly than the economy as a whole. MPH benefits systematically from this through the growth of HAEMATO AG with drugs in the insurance-financed health care market and M1 Kliniken AG in the private payer market, the so-called second health care market.

“In recent years, a dividend of 12 cents per share has been paid. Based on the positive results of the last three years, we will propose a dividend of 20 cents per share for 2017 to the Annual General Meeting,” says Patrick Brenske, MPH Board Member.

read more

2017

30. October 2017 - Q3 Results 2017

Preliminary IFRS results in the first nine month of 2017

Berlin, 30. October 2017 – MPH Health Care AG: Growth in the third quarter of 2017

  • Value of portfolio holdings increases by 6,68% to EUR 226,67 million
  • Equity ratio increases to 93%
  • Positive development in the healthcare market

In the first nine months of 2017, MPH achieved a preliminary IFRS net income of EUR 11.22 million. Equity increased from EUR 213.95 million in the previous year to EUR 220.03 million.

The share price of MPH rose by 13.2% to EUR 3.43 compared to the third quarter of 2016. The net asset value per share increased to EUR 5.14. The increase in value of MPH’s portfolio holdings resulted in net income for the third quarter of EUR 13.42 million.

MPH’s portfolio companies HAEMATO AG (pharma) and M1 Kliniken AG (clinics) are benefiting from the continued positive development within their growth segments. HAEMATO AG, a specialist in oncology, HIV and other chronic diseases, generates further growth through the high demand for personalized medicine. The market volume is around EUR 10 billion and is growing at an annual rate of 10%.

Kliniken AG benefits from the rapidly growing beauty market. With now more than 50 doctors and 15 locations in Germany, M1 is the leading chain of clinics in major segments of beauty medicine. The growth amounts to approx. 20% -30% p.a.. The company’s aim is to open up further locations also internationally and at the same time to steadily expand the treatment offer in the outpatient area.

The real estate developer CR Capital Real Estate AG increased their sales quota to more than 50% for the first construction phase of the property in Schkeuditz at Leipzig.

read more

31. August 2017 - Interim Report 2017

Interim Report 2017

Berlin, 31 August 2017 – MPH Health Care AG strengthened its activities in the health care market; Net asset value (NAV) per share and share price significantly increased compared to the previous year’s period

• Increase in the net asset value of the share by 35% to EUR 4.83

• Share price rose by 46% to EUR 3.66 (compared to 30 June 2016). Valuation gap partially closed.

This year’s Annual General Meeting decided to rename MPH into “MPH Health Care AG”. This intends to make it even clearer that MPH acts as an investment company aiming at the development of entrepreneurial opportunities in the health care market. As in the previous year a dividend payment of € 0.12 / share was decided.

In the first half of 2017, MPH Health-Care AG successfully continued its growth path. Our company and our holdings were able to record a very gratifying development overall. MPH’s net asset value per share rose by 35% from EUR 3.58 to EUR 4.83 compared to the previous year’s period. At the end of the first half-year of 2017, the share price rose by 45.8% compared to June 30, 2016 (price on June 30, 2016: EUR 2.56 / share). This increase closed some of the remaining valuation gap to about 24%.

The company will provide the interim report for the reporting period from January 1, 2017 to June 30, 2017 as of today.

read more

7. July 2017 - Change in Management Board

First quarter 2017: Preliminary IFRS-Result, period loss – EUR 2.39 million. Equity EUR 211.56 million and thereby EUR 4.94 per share. Publication of the annual report 2016 on April, 28, 2017.

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), announces the preliminary IFRS result for the first quarter of 2017. In the first quarter of 2017, the preliminary IFRS loss for the period was EUR -2.39 million. The reason for the loss in the period is the lower share price level of the shareholdings on March 31, 2017, compared to the share prices on December 31, 2016.

“We are positively assessing the operating performance in the first quarter of 2017 of HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG. We are confident about the further development in 2017 despite the short-term decline in the share price. It remains the case that the Management Board proposes an unchanged dividend compared to last year, which is 12 cents per share, at the Annual General Meeting, “said Patrick Brenske and Dr. Christian Pahl, MPH Board Members.

On this day MPH will publish the annual report 2016 on the website. As already provisionally announced, the annual net profit for the year of MPH amounted to EUR 80.1 million for the financial year 2016.

read more

28. April 2017 - Q1 Results 2017

First quarter 2017: Preliminary IFRS-Result, period loss – EUR 2.39 million. Equity EUR 211.56 million and thereby EUR 4.94 per share. Publication of the annual report 2016 on April, 28, 2017.

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), announces the preliminary IFRS result for the first quarter of 2017. In the first quarter of 2017, the preliminary IFRS loss for the period was EUR -2.39 million. The reason for the loss in the period is the lower share price level of the shareholdings on March 31, 2017, compared to the share prices on December 31, 2016.

“We are positively assessing the operating performance in the first quarter of 2017 of HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG. We are confident about the further development in 2017 despite the short-term decline in the share price. It remains the case that the Management Board proposes an unchanged dividend compared to last year, which is 12 cents per share, at the Annual General Meeting, “said Patrick Brenske and Dr. Christian Pahl, MPH Board Members.

On this day MPH will publish the annual report 2016 on the website. As already provisionally announced, the annual net profit for the year of MPH amounted to EUR 80.1 million for the financial year 2016.

read more

17. March 2017 - Preliminary IFRS-Results 2016

2016: Temporary IFRS results, annual net profit of €81.45m, €1.90 profit per share (previous year: €84.10m, €1.96 profit per share). Equity €215.33m (previous year: €139.02m).

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), announces the temporary IFRS group results for fiscal year 2016. In fiscal year 2016, the temporary IFRS annual net profit was €81.45m (€1.90 profit per share).

“HAEMATO AG, M1 Kliniken AG, and CR Capital Real Estate AG holding companies listed in the Frankfurt Stock Exchange operated successfully in 2016.
In fiscal year 2016, HAEMATO achieved an increase in turnover of 20%, an EBIT growth of 63%, and an increase of the annual net profit of 94%.

During the fiscal year, the HAEMATO share price increased from €4.94 to €6.44. As in the previous year, the dividend paid in June 2016 was €0.30 per share.

M1 Kliniken AG expanded its clinic in Berlin to 6 operating theatres and 35 patient beds. After some more openings, 13 M1 centres of competence are now ready to serve our customers throughout Germany. The financial data for 2016 will be published on 31.03.2017.

The M1 share price has almost doubled from €5.34 to €10.55 during the fiscal year. The dividend paid in June 2016 was €0.30 per share.

CR Capital Real Estate AG reported progress in the project developments at the annual general meeting on 18.08.2016. The 2016 financial data will presumably be published in March 2017.

Following last year’s annual net profit of €84.10m, the annual net profit of €81.45m is another record result. This allows us to be confident regarding the further development in 2017. In each year since 2005, the health care industry has expanded its gross value added more strongly than the overall economy. MPH systematically benefits from the growth of HAEMATO AG in the field of pharmaceuticals in the insurance-financed market and through the growth of M1 Kliniken AG in the direct-payer market, the so-called secondary health care market.

The results situation allows us to propose at the annual general meeting a dividend of €0.12 per share, which is the same amount as last year”, note both Patrick Brenske and Dr Christian Pahl, Members of the Board of MPH.

read more